Walter J. Curran Jr., former executive director of Winship Cancer Institute of Emory University, was named chief of Piedmont Oncology Institute (Piedmont Oncology), effective Jan. 9.
Treatment with an indefinite course of osimertinib dramatically improves progression-free survival for patients with stage 3 non-small cell cancer, according to the results of the LAURA trial. The median PFS was 39.1 months in the osimertinib group, compared to 5.6 months with the placebo group.
